Post by Vall d'Hebron Institute of Oncology (VHIO)

🔴 Final results from the #CALYPSO trial, senior-authored by Cristina Suárez (#VHIO), show that a novel treatment combination improves overall survival in patients with MET-altered metastatic papillary renal cancer. 🗞️ Published in Journal of Clinical Oncology, this phase II study highlights the potential of combining the MET inhibitor savolitinib with the PD-1 inhibitor durvalumab, offering a promising therapeutic strategy for a patient population with limited treatment options. These findings also support the ongoing phase III SAMETA trial, further advancing research into targeted therapies and precision medicine approaches in renal cancer. ➡️ Discover more: https://lnkd.in/e66Sj748 #Oncology | #ClinicalTrials | #PrecisionMedicine